Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice.

"the scrna-seq and sctcr-seq data generated during this study are available at geo under the following accession number: gse228233 ."

"code generated for this study is available at: https://github com/jennacollier/nod_spt_pd1 ."

"Disclosures: A.H. Sharpe reported grants from National Institutes of Health P01 AI56299, P01 AI39671, and P01 108545, and grants from Vertex during the conduct of the study. A.H. Sharpe reported personal fees from Surface Oncology, Sqz Biotech, Selecta, Elpiscience, Bicara, Fibrogen, Alixia, GlaxoSmith Kline, Janssen, and Amgen; “other” from Monopteros, IOME, and Corner Therapeutics; and grants from Merck, Roche, Ipsen, Novartis, Quark Ventures, AbbVie, Moderna, and Erasca outside the submitted work; in addition, A.H. Sharpe had a patent number 7,432,059 with royalties paid Roche, Merck, Bristol-Myers-Squibb, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Leica, Mayo Clinic, Dako, and Novartis; a patent number 7,722,868 with royalties paid Roche, Merck, Bristol-Myers-Squibb, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Leica, Mayo Clinic, Dako, and Novartis; a patent number 8,652,465 licensed “Roche”; a patent number 9,457,080 licensed “Roche”; a patent number 9,683,048 licensed “Novartis”; a patent number 9,815,898 licensed “Novartis”; a patent number 9,845,356 licensed “Novartis”; a patent number 10,202,454 licensed “Novartis”; a patent number 10,457,733 licensed “Novartis”; a patent number 9,580,684 issued “none”; a patent number 9,988,452 issued “none”; a patent number 10,370,446 issued “none”; a patent to 10,457,733 issued; a patent number 10,752,687 issued; a patent number 10,851,165 issued; and a patent number 10,934,353 issued. A.H. Sharpe is on the scientific advisory boards for the Massachusetts General Cancer Center, Program in Cellular and Molecular Medicine at Boston Children’s Hospital, the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, the Bloomberg-Kimmel Institute for Cancer Immunotherapy, the Gladstone Institute, and Bioentre. She is an academic editor for the Journal of Experimental Medicine. No other disclosures were reported."

"This work was supported by funding from the National Institutes of Health, grants P01 AI56299, P01AI039671, P01 AI108545, and Vertex. Disclosures: A.H. Sharpe reported grants from National Institutes of Health P01 AI56299, P01 AI39671, and P01 108545, and grants from Vertex during the conduct of the study. A.H. Sharpe reported personal fees from Surface Oncology, Sqz Biotech, Selecta, Elpiscience, Bicara, Fibrogen, Alixia, GlaxoSmith Kline, Janssen, and Amgen; “other” from Monopteros, IOME, and Corner Therapeutics; and grants from Merck, Roche, Ipsen, Novartis, Quark Ventures, AbbVie, Moderna, and Erasca outside the submitted work; in addition, A.H. Sharpe had a patent number 7,432,059 with royalties paid Roche, Merck, Bristol-Myers-Squibb, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Leica, Mayo Clinic, Dako, and Novartis; a patent number 7,722,868 with royalties paid Roche, Merck, Bristol-Myers-Squibb, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Leica, Mayo Clinic, Dako, and Novartis; a patent number 8,652,465 licensed “Roche”; a patent number 9,457,080 licensed “Roche”; a patent number 9,683,048 licensed “Novartis”; a patent number 9,815,898 licensed “Novartis”; a patent number 9,845,356 licensed “Novartis”; a patent number 10,202,454 licensed “Novartis”; a patent number 10,457,733 licensed “Novartis”; a patent number 9,580,684 issued “none”; a patent number 9,988,452 issued “none”; a patent number 10,370,446 issued “none”; a patent to 10,457,733 issued; a patent number 10,752,687 issued; a patent number 10,851,165 issued; and a patent number 10,934,353 issued. A.H. Sharpe is on the scientific advisory boards for the Massachusetts General Cancer Center, Program in Cellular and Molecular Medicine at Boston Children’s Hospital, the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, the Bloomberg-Kimmel Institute for Cancer Immunotherapy, the Gladstone Institute, and Bioentre. She is an academic editor for the Journal of Experimental Medicine. No other disclosures were reported."